Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 3 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Dyno Therapeutics Inc. is managing 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 6 actions are distributed among 5 distinct examiners and 3 distinct art units. M Franco G Salvoza is the busiest examiner, with 2 of the 6 pending actions currently assigned to them.
The fact that 5 examiners are assigned to 6 actions means that most examiners are only handling a single case for the company. The 3 art units involved indicate that the pending matters are concentrated within a small number of specialized technical groups. Practitioners must manage the 2 actions under M Franco G Salvoza while addressing the requirements of the other examiners. This distribution of 6 actions ensures that a variety of perspectives are applied to the company's biotechnology and pharmaceutical applications. The involvement of 3 art units requires a prosecution approach that can adapt to the specific standards of multiple technical departments. With 5 distinct examiners involved, the company must maintain consistent arguments while addressing the individual preferences of each reviewer. This structure provides a diverse but manageable prosecution landscape for the company's current pending matters, allowing for a high degree of attention to each of the 6 pending actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §102 only | 1 (17%) |
| §112 only | 1 (17%) |
| Double-patenting only | 2 (33%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALVOZA, M FRANCO G | 2 | 68.2% | +30.6% |
| MONTANARI, DAVID A | 1 | 64.8% | +49.0% |
| CHESTNUT, BARRY A | 1 | 73.9% | +6.3% |
| CORNELIUS, CLAIRE ADRIENNE | 1 | 71.4% | +0.0% |
| PENNINGTON, KATIE LEIGH | 1 | 31.8% | +58.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042890 | IMPROVED DEPENDOPARVOVIRUS PRODUCTION COMPOSITIONS AND METHODS | PENNINGTON, KATIE LEIGH | 29d |
| 18571367 | CAPSID VARIANTS AND METHODS OF USING THE SAME | CORNELIUS, CLAIRE ADRIENNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042890 | IMPROVED DEPENDOPARVOVIRUS PRODUCTION COMPOSITIONS AND METHODS | PENNINGTON, KATIE LEIGH | 29d |
| 19537081 | CAPSID POLYPEPTIDES AND METHODS OF USE THEREOF | MONTANARI, DAVID A | — |
| 18779855 | CAPSID VARIANTS AND METHODS OF USING THE SAME | SALVOZA, M FRANCO G | — |
| 18761730 | CAPSID VARIANTS AND METHODS OF USING THE SAME | SALVOZA, M FRANCO G | — |
| Art Unit | Apps |
|---|---|
| 1672 | 4 |
| 1632 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19537081 | CAPSID POLYPEPTIDES AND METHODS OF USE THEREOF | MONTANARI, DAVID A | 1632 | §112 | Final Rejection | — | Pending | Feb 11, 2026 |
| 18779855 | CAPSID VARIANTS AND METHODS OF USING THE SAME | SALVOZA, M FRANCO G | 1672 | DP | Non-Final OA | — | Pending | Jul 22, 2024 |
| 18761730 | CAPSID VARIANTS AND METHODS OF USING THE SAME | SALVOZA, M FRANCO G | 1672 | DP | Non-Final OA | — | Pending | Jul 02, 2024 |
| 18573582 | CAPSID VARIANTS AND METHODS OF USING THE SAME | CHESTNUT, BARRY A | 1672 | §102 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18571367 | CAPSID VARIANTS AND METHODS OF USING THE SAME | CORNELIUS, CLAIRE ADRIENNE | 1672 | §101§112 | Final Rejection | — | Pending | Dec 18, 2023 |
| 18042890 | IMPROVED DEPENDOPARVOVIRUS PRODUCTION COMPOSITIONS AND METHODS | PENNINGTON, KATIE LEIGH | 1634 | §103§112 | Final Rejection | 29d | Pending | Feb 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDyno Therapeutics Inc. has 6 pending office actions as of October 2026, spread across 3 art units and 5 examiners.
M Franco G Salvoza has the most, with 2 of Dyno Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
